- Could Your Grocery Store Meat Be Causing Recurring UTIs?
- Are You Making This Expensive Thermostat Error This Winter?
- Recognizing the Signs of Hypothyroidism
- 10 Strategies to Overcome Insomnia
- Could Artificial Sweeteners Be Aging the Brain Faster?
- Techniques for Soothing Your Nervous System
- Does the Water in Your House Smell Funny? Here’s Why
- Can a Daily Dose of Apple Cider Vinegar Actually Aid Weight Loss?
- 6 Health Beverages That Can Actually Spike Your Blood Sugar
- Treatment Options for Social Anxiety Disorder
Intarosa Approved for Post-Menopausal Pain During Sex
Intarosa has been approved by the U.S. Food and Drug Administration to treat women who have moderate-to-severe pain during sexual intercourse caused by post-menopausal vulvar and vaginal atrophy (VVA).
As the FDA explained, during menopause estrogen levels can decline in vaginal tissues, leading to VVA.
The product, contained in a once-daily insert, is the first approved to include the active ingredient prasterone, also known as dehydroepiandrosterone (DHEA), the agency said Thursday in a news release.
The product’s effectiveness was established in two 12-week clinical trials involving 406 post-menopausal women, aged 40 to 80. The most common adverse reactions included vaginal discharge and abnormal Pap smear, a test used to detect cervical cancer.
DHEA is contained in some dietary supplements, although the FDA said it hasn’t evaluated the safety and effectiveness of such supplements.
Intarosa is marketed by Endoceutics Inc., based in Quebec, Canada.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2026 HealthDay. All rights reserved.










